Androxal
Sponsors
Repros Therapeutics Inc.
Conditions
Drug-drug InteractionPharmacokineticsSecondary HypogonadismTolerabilityType 2 Diabetes Mellitus
Phase 1
A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal
CompletedNCT01959685
Start: 2013-10-31End: 2013-11-30Updated: 2014-08-11
Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
CompletedNCT01991327
Start: 2014-05-31End: 2014-07-31Updated: 2014-08-11
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration
CompletedNCT02274181
Start: 2014-12-31End: 2015-01-31Updated: 2015-03-12
Phase 2
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
CompletedNCT01191320
Start: 2010-10-31End: 2011-12-31Updated: 2014-07-24
Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
CompletedNCT01270841
Start: 2011-01-31End: 2011-12-31Updated: 2014-07-28
Phase 3
Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism
CompletedNCT00962637
Start: 2006-03-31End: 2007-05-31Updated: 2010-02-11
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
CompletedNCT01067365
Start: 2006-03-31End: 2007-05-31Updated: 2014-06-27
Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
CompletedNCT01532414
Start: 2012-08-31End: 2013-03-31Updated: 2015-05-27
Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
CompletedNCT01534208
Start: 2012-05-31End: 2013-10-31Updated: 2014-07-24
An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
CompletedNCT01739582
Start: 2012-11-30End: 2014-04-30Target: 300Updated: 2014-04-16